Timber Pharmaceuticals — Technical Presentation (November 2021)
14 slides from Timber Pharmaceuticals's technical presentation, Nov 22, 2021
Slide 1: Building Bridges in Medical Dermatology: Phase 2b CONTROL Study Results
Building Bridges in Medical Dermatology TMB - 001 Phase 2b CONTROL Study Results Conference Call November 22, 2021 NYSE American: TMBR
Slide 2: Safe Harbor Statement
NYSE American: TMBR Safe Harbor Statement 2 Certain statements contained in this PowerPoint presentation describing Timber’s technology and development program, including, without limitation, statements containing the words “expects,” “anticipates,” “believes,” and words of similar import, constitut
Slide 3: Strategic Pipeline in Rare Dermatologic Disease
NYSE American: TMBR Strategic Pipeline in Rare Dermatologic Disease 3
Slide 4: Unmet Need for Congenital Ichthyosis
NYSE American: TMBR Unmet Need: An efficacious and safe treatment that can be used long term to cover a large body surface area . 4 TMB - 001 for Congenital Ichthyosis A rare disorder of keratinization affecting ~ 80,000 people in the U.S. (>1.5 million globally) Prevalence • X - Linked Ichthyosis
Slide 5: Topical Isotretinoin in CI
NYSE American: TMBR 5 TMB - 001 Topical Isotretinoin in CI Patented topical formulation minimizing systemic absorption and allowing for chronic treatment Isotretinoin is well known as the most effective therapy for several skin conditions, including ichthyosis, but it is only available orally, whe
Slide 6: Phase IIB Design - Scale Severity
6 1<6($PHULFDQ 70%5 3KDVH,,% 'HVLJQ ² 6FDOH 6HYHULW\
Slide 7: Phase IIB Design - Scale Severity
7 1<6($PHULFDQ 70%5 3KDVH,,% 'HVLJQ ² 6FDOH 6HYHULW\
Slide 8: Investigator's Global Assessment (IGA) Score Point Scale
NYSE American: TMBR 8 Investigator’s Global Assessment (IGA) Score -- 5 - Point Scale 0 Clear No scaling and no roughness, no fissure 1 Almost Clear Occasional fine scales, hardly palpable roughness (mostly smooth) no fissure 2 Mild Small and fine scales predominate, no more than a few large scales,
Slide 9: Topical Isotretinoin in CI Phase 2B Study Design (CONTROL Study)
NYSE American: TMBR 9 TMB - 001 Topical Isotretinoin in CI Phase 2B Study Design (CONTROL Study) Title A Vehicle Controlled Study to Evaluate Safety and Efficacy of Topical TMB - 001 for Treatment of Congenital Ichthyosis Primary Objective Proportion of subjects with Visual Index of Ichthyosis Sever
Slide 10: CONTROL Study - Efficacy Intent to Treat (ITT)
NYSE American: TMBR 10 TMB - 001 CONTROL Study - Efficacy Intent to Treat (ITT) 64% of the ITT Population in 0.05% dose achieved a 50% reduction in VIIIS score versus 33% in the vehicle group (nominal p=.17) 55% of the Per Protocol Population in 0.05% dose achieved a 2 point reduction in IGA versus
Slide 11: CONTROL Study - Efficacy Per Protocol
NYSE American: TMBR 11 TMB - 001 CONTROL Study - Efficacy Per Protocol 100% of the Per Protocol Population in 0.05% dose achieved a 50% reduction in VIIIS score versus 40% in the vehicle group (nominal p=.04) 100% of the Per Protocol Population in 0.05% dose achieved a 2 point reduction in IGA versu
Slide 12: CONTROL Study - Lamellar Ichthyosis Responder Patient
NYSE American: TMBR 12 TMB - 001 CONTROL Study - 21 yr. old patient with Lamellar Ichthyosis (ALOX12B) - 0.05% arm (responder) End Of Study – Visit 6 Baseline
Slide 13: Significant Clinical Milestones on a Quarterly Basis over next 12 months
NYSE American: TMBR Significant Clinical Milestones on a Quarterly Basis over next 12 months 13 TMB - 001 TMB - 002 Q4 2021 Topline Data for Phase IIb Trial Completed Enrollment of Phase IIb Q1 2022 End of Phase II FDA Meeting Broad Phase IIb Data Dissemination Q2 2022 Anticipated Start of Phase III
Slide 14: Investor Information Contact
www.timberpharma.com For additional Investor Information please contact: John Koconis Stephanie Prince Chairman and CEO PCG Advisory [email protected] [email protected] (646) 863 - 6341 NYSE American: TMBR
Timber Pharmaceuticals — Technical Presentation (November 2021) on 6ix